Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.

Article  CAS  Google Scholar 

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30. https://doi.org/10.1093/eurheartj/ehz962.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA, /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50. https://doi.org/10.1016/j.cjca.2021.03.016.

Article  PubMed  Google Scholar 

Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pena JM, et al. Role of apolipoprotein B in the Clinical Management of Cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024. https://doi.org/10.1016/j.jacl.2024.08.013.

Article  PubMed  Google Scholar 

Cholesterol Treatment Trialists C. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–45. https://doi.org/10.1016/S0140-6736(22)01545-8.

Article  Google Scholar 

Iatan I, Mancini GBJ, Yeoh E, Hegele RA. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management. Expert Rev Cardiovasc Ther. 2023;21(6):423–35. https://doi.org/10.1080/14779072.2023.2215982.

Article  PubMed  CAS  Google Scholar 

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410. https://doi.org/10.1016/j.jacc.2016.02.071.

Article  PubMed  CAS  Google Scholar 

Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA Scientific Statement on Statin Intolerance: a New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient. J Clin Lipidol. 2022;16(4):361–75. https://doi.org/10.1016/j.jacl.2022.05.068

Article  PubMed  Google Scholar 

Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis. 2019;18(1):175. https://doi.org/10.1186/s12944-019-1099-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003

Article  PubMed  Google Scholar 

Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23. https://doi.org/10.5114/aoms.2015.49807.

Article  PubMed  PubMed Central  Google Scholar 

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. https://doi.org/10.1161/ATV.0000000000000073.

Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167(4):221–7. https://doi.org/10.7326/M16-0838.

Article  PubMed  Google Scholar 

Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the national lipid association. J Clin Lipidol. 2023;17(1):19–39. https://doi.org/10.1016/j.jacl.2022.09.001.

Article  PubMed  Google Scholar 

Guyton JR, Bays HE, Grundy SM, Jacobson TA, The national lipid association statin intolerance P. an assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81. https://doi.org/10.1016/j.jacl.2014.03.002

Article  PubMed  Google Scholar 

Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol. 2016;32(7 Suppl):S35–65. https://doi.org/10.1016/j.cjca.2016.01.003.

Article  PubMed  Google Scholar 

Sposito AC, Faria Neto JR, Carvalho LS, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the luso-latin American consortium. Curr Med Res Opin. 2017;33(2):239–51. https://doi.org/10.1080/03007995.2016.1252740.

Article  PubMed  CAS  Google Scholar 

Cheeley MK, Clegg K, Lockridge C, Schubert TJ, Jones LK. Statin intolerance: an overview of US and international guidance. Curr Atheroscler Rep. 2023;25(8):517–26. https://doi.org/10.1007/s11883-023-01124-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The national lipid association’s muscle safety expert panel. an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71. https://doi.org/10.1016/j.jacl.2014.03.004.

Article  PubMed  Google Scholar 

Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):C52–60. https://doi.org/10.1016/j.amjcard.2005.12.010.

Article  CAS  Google Scholar 

Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101.

Article  PubMed  CAS  Google Scholar 

Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90. https://doi.org/10.1001/jama.2016.3608.

Article  PubMed  CAS  Google Scholar 

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–69. https://doi.org/10.1016/j.jacl.2015.08.006.

Article  PubMed  Google Scholar 

Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135.

Article  PubMed  PubMed Central  Google Scholar 

Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–22. https://doi.org/10.1016/j.jacc.2021.07.022.

Article  PubMed  PubMed Central  CAS